489 related articles for article (PubMed ID: 15619115)
1. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
[TBL] [Abstract][Full Text] [Related]
2. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
Linden AM; Greene SJ; Bergeron M; Schoepp DD
Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
[TBL] [Abstract][Full Text] [Related]
4. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
Linden AM; Bergeron M; Schoepp DD
Neuropharmacology; 2005; 49 Suppl 1():120-34. PubMed ID: 16023151
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
6. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus.
Linden AM; Baez M; Bergeron M; Schoepp DD
Neuropharmacology; 2006 Aug; 51(2):213-28. PubMed ID: 16733060
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
8. Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective.
Caraci F; Molinaro G; Battaglia G; Giuffrida ML; Riozzi B; Traficante A; Bruno V; Cannella M; Merlo S; Wang X; Heinz BA; Nisenbaum ES; Britton TC; Drago F; Sortino MA; Copani A; Nicoletti F
Mol Pharmacol; 2011 Mar; 79(3):618-26. PubMed ID: 21159998
[TBL] [Abstract][Full Text] [Related]
9. Selective activation of either mGlu2 or mGlu3 receptors can induce LTD in the amygdala.
Lucas SJ; Bortolotto ZA; Collingridge GL; Lodge D
Neuropharmacology; 2013 Mar; 66():196-201. PubMed ID: 22531751
[TBL] [Abstract][Full Text] [Related]
10. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.
Marek GJ; Wright RA; Schoepp DD; Monn JA; Aghajanian GK
J Pharmacol Exp Ther; 2000 Jan; 292(1):76-87. PubMed ID: 10604933
[TBL] [Abstract][Full Text] [Related]
11. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
[TBL] [Abstract][Full Text] [Related]
12. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
Tizzano JP; Griffey KI; Schoepp DD
Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
[TBL] [Abstract][Full Text] [Related]
13. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
[TBL] [Abstract][Full Text] [Related]
14. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain.
Felder CC; Schober DA; Tu Y; Quets A; Xiao H; Watt M; Siuda E; Nisenbaum E; Xiang C; Heinz B; Prieto L; McKinzie DL; Monn JA
J Pharmacol Exp Ther; 2017 Apr; 361(1):190-197. PubMed ID: 28138041
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
[TBL] [Abstract][Full Text] [Related]
16. Differentiating the roles of mGlu2 and mGlu3 receptors using LY541850, an mGlu2 agonist/mGlu3 antagonist.
Hanna L; Ceolin L; Lucas S; Monn J; Johnson B; Collingridge G; Bortolotto Z; Lodge D
Neuropharmacology; 2013 Mar; 66():114-21. PubMed ID: 22445601
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent.
Higgins GA; Ballard TM; Kew JN; Richards JG; Kemp JA; Adam G; Woltering T; Nakanishi S; Mutel V
Neuropharmacology; 2004 Jun; 46(7):907-17. PubMed ID: 15081787
[TBL] [Abstract][Full Text] [Related]
18. Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.
Schweitzer C; Kratzeisen C; Adam G; Lundstrom K; Malherbe P; Ohresser S; Stadler H; Wichmann J; Woltering T; Mutel V
Neuropharmacology; 2000 Jul; 39(10):1700-6. PubMed ID: 10884552
[TBL] [Abstract][Full Text] [Related]
19. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist.
Schoepp DD; Johnson BG; Wright RA; Salhoff CR; Monn JA
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):175-80. PubMed ID: 9750002
[TBL] [Abstract][Full Text] [Related]
20. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
Johnson MP; Barda D; Britton TC; Emkey R; Hornback WJ; Jagdmann GE; McKinzie DL; Nisenbaum ES; Tizzano JP; Schoepp DD
Psychopharmacology (Berl); 2005 Apr; 179(1):271-83. PubMed ID: 15717213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
